SCHEMBL12284628

SCHEMBL12284628

CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(SOON)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 8/20 0.64
ADRA1A P35348 8/20 0.64
ADRA1B P35368 8/20 0.64
ADRB2 P07550 3/20 0.64
ADRB1 P08588 1/20 0.64
HTR1A P08908 1/20 0.64
ADRA2A P08913 1/20 0.64
DRD2 P14416 1/20 0.64
ADRA2B P18089 1/20 0.64
ADRA2C P18825 1/20 0.64
HTR2A P28223 1/20 0.64
HTR7 P34969 1/20 0.64
OPRM1 P35372 1/20 0.64
DRD3 P35462 1/20 0.64
HTR2B P41595 1/20 0.64
KCNH2 Q12809 1/20 0.64
SIGMAR1 Q99720 7/20 0.48
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10820229 1.00 ADRA1D (0.64) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL12284587 0.90 ADRA1D (0.61) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL13623737 0.89 ADRA1D (0.50) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL13623722 0.89 ADRA1D (0.50) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL51245 0.87 ADRA1D (0.67) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL9548034 0.87 ADRA1D (0.67) ADRA1DADRA1AADRA1BADRB2ADRB1
Hydrochloric Acid SCHEMBL9548113 0.86 ADRA1D (0.66) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL11218388 0.84 ADRA1D (0.66) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL14018837 0.82 SIGMAR1 (0.49) ADRA1DADRA1AADRA1BADRB2ADRB1
SCHEMBL14275116 0.82 SMN1; SMN2 (0.47) ADRA1DADRA1AADRA1BADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9198904-B2 Pharmaceutical composition for oral administration ASTELLAS PHARMA INC. (JP) 2015-12-01 US disclosed
US-8017803-B2 Process for the preparation of tamsulosin and intermediates thereof HOVIONE INTER LTD. (CH) 2011-09-13 US disclosed
US-20100331361-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALPHA-ADRENERGIC RECEPTOR ANTAGONIST AND AN ANTI-MUSCARINIC AGENT AND METHOD OF IMPROVING LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH PROSTATIC HYPERTROPHY ASTELLAS PHARMA INC. (JP) 2010-12-30 US disclosed
US-20100261770-A1 PHARMACEUTICAL COMPOSITION FOR IMPROVING LOWER URINARY TRACT SYMPTOMS ASTELLAS PHARMA INC. (JP) 2010-10-14 US disclosed
US-20100233260-A1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ASTELLAS PHARMA INC. (JP) 2010-09-16 US disclosed
US-7638649-B2 Method of preparation of (R)-(−)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide ZENTIVA, K.S. (CZ) 2009-12-29 US disclosed
US-20090234154-A1 Process for the preparation of tamsulosin and intermediates thereof HOVIONE INTER LTD. 2009-09-17 US disclosed
US-20080319225-A1 Method of Preparation of (R)-(-)-5(2-Aminopropyl)-2-Methoxybenzenesulfonamide ZENTIVA, A.S. (CZ) 2008-12-25 US disclosed
US-7329780-B2 Method of preparing optically pure phenethylamine derivatives CJ CORPORATION (KR) 2008-02-12 US disclosed
US-20070269514-A1 TABLET COMPOSITION WITH A PROLONGED RELEASE OF TAMSULOSIN SYNTHON BV (NL) 2007-11-22 US disclosed
US-7282606-B2 Process for preparation of tamsulosin and its aralkylamine derivatives WELL-BEING BIOCHEMICAL CORP. (TW) 2007-10-16 US disclosed
US-20070197828-A1 Method of preparing optically pure phenethylamine derivatives CJ CORPORATION (KR) 2007-08-23 US disclosed
US-20070015939-A1 Process for preparation of tamsulosin and its aralkylamine derivatives WELL-BEING BIOCHEMICAL CORP (TW) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070269514-A1 TABLET COMPOSITION WITH A PROLONGED RELEASE OF TAMSULOSIN PTGER1, PTGER2, PTGER3 ADRA1D 21/4885ADRA1A 29/4885ADRA1B 15/4885
US-20090234154-A1 Process for the preparation of tamsulosin and intermediates thereof AVPR2, AVPR1B, TACR2 ADRA1D 31/4885ADRA1A 57/4885ADRA1B 9/4885
US-20080319225-A1 Method of Preparation of (R)-(-)-5(2-Aminopropyl)-2-Methoxybenzenesulfonamide NPSR1, TPSAB1, TPSB2 ADRA1D 22/4885ADRA1A 45/4885ADRA1B 10/4885
US-20100331361-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALPHA-ADRENERGIC RECEPTOR ANTAGONIST AND AN ANTI-MUSCARINIC AGENT AND METHOD OF IMPROVING LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH PROSTATIC HYPERTROPHY ADRB1, ADRA2B, ADRB3 ADRA1D 9/4885ADRA1A 6/4885ADRA1B 5/4885
US-20070197828-A1 Method of preparing optically pure phenethylamine derivatives KMT2A, PNMT, PTMA ADRA1D 92/4885ADRA1A 5/4885ADRA1B 57/4885
US-20100261770-A1 PHARMACEUTICAL COMPOSITION FOR IMPROVING LOWER URINARY TRACT SYMPTOMS BPHL, REN, PRSS2 ADRA1D 333/4885ADRA1A 501/4885ADRA1B 210/4885
US-20070015939-A1 Process for preparation of tamsulosin and its aralkylamine derivatives ADRB1, ADRA2B, ADRA2A ADRA1D 7/4885ADRA1A 5/4885ADRA1B 4/4885
US-20100233260-A1 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION ADRB3, ADRB1, ADRA1B ADRA1D 5/4885ADRA1A 9/4885ADRA1B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.